Department of Pathology, Tianjin Union Medical Center, Tianjin, 300121, People's Republic of China.
Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, People's Republic of China.
Med Oncol. 2019 Aug 12;36(9):82. doi: 10.1007/s12032-019-1303-z.
Our previous work has demonstrated that paclitaxel can induce the formation of polyploid giant cancer cells (PGCCs) and inhibit tumor growth by reprogramming ovarian cancer epithelial cells to a benign fibroblastic state via epithelial-mesenchymal transition. Here, triptolide (TPL) was used to treat the breast and ovarian cancer lines. The morphologic characteristics and EMT-related protein expression were studied in different generation of cancer cells after TPL treatment. When BT-549 and HEY cells reached 80-90% confluence, TPL was added to BT-549 for 48 h and HEY for 9 h at a concentration of 40 ng/ml. Scattered PGCCs survived from TPL treatment and generated daughter cells, and then were cultured in medium without TPL for at least ten generation. Western blot analysis and immunocytochemical staining were performed to detect the expression levels and subcellular location of EMT-related proteins in control cells and different generation of TPL-induced PGCCs with daughter cells. Furthermore, wound-healing, transwell, cell counting kit-8, and MTT assay were used to compare the alternation of migration, invasion, and proliferation among control cells and different generation of TPL-induced PGCCs with daughter cells. Scattered PGCCs survived from the treatment of TPL and produced small-sized daughter cells 20-30 days after treatment. Compared to the control cells, the first generation of TPL-induced PGCCs with their daughter cells differentially expressed EMT-related proteins including fibronectin, E-cadherin, vimentin, and Twist, and had lower migration, invasion, and proliferation abilities. The abilities of migration, invasion, and proliferation of TPL-induced PGCCs with their daughter cells gradually enhanced as the passages increasing, and markedly exceeded the control cells in the tenth generation. TPL-induced PGCCs with their daughter cells gradually obtain the abilities of invasion and metastasis in vitro as the number of passage increasing, which can be used to mimick the cancer cells subjected to anti-cancer drugs in vivo and may provide some new insights to explore the mechanism of cancer invasion, metastasis and relapse after chemotherapy.
我们之前的工作表明,紫杉醇可以通过上皮-间充质转化将卵巢癌细胞重编程为良性成纤维细胞状态,从而诱导多倍体巨癌细胞(PGCCs)的形成并抑制肿瘤生长。在这里,雷公藤红素(TPL)被用于治疗乳腺癌和卵巢癌细胞系。研究了 TPL 处理后不同代癌细胞的形态特征和 EMT 相关蛋白表达。当 BT-549 和 HEY 细胞达到 80-90%汇合时,将 TPL 添加到 BT-549 中 48 小时,添加到 HEY 中 9 小时,浓度为 40ng/ml。从 TPL 处理中存活下来的散在 PGCC 产生了子细胞,然后在没有 TPL 的培养基中培养至少 10 代。Western blot 分析和免疫细胞化学染色用于检测 EMT 相关蛋白在对照细胞和不同代 TPL 诱导的 PGCC 及其子细胞中的表达水平和亚细胞定位。此外,划痕愈合、Transwell、细胞计数试剂盒-8 和 MTT 测定用于比较对照细胞和不同代 TPL 诱导的 PGCC 及其子细胞之间迁移、侵袭和增殖的变化。从 TPL 处理中存活下来的散在 PGCC 产生了 20-30 天后治疗的小尺寸子细胞。与对照细胞相比,第一代 TPL 诱导的 PGCC 及其子细胞表达差异 EMT 相关蛋白,包括纤维连接蛋白、E-钙粘蛋白、波形蛋白和 Twist,迁移、侵袭和增殖能力较低。随着传代增加,TPL 诱导的 PGCC 及其子细胞的迁移、侵袭和增殖能力逐渐增强,在第十代时明显超过对照细胞。随着传代次数的增加,TPL 诱导的 PGCC 及其子细胞逐渐获得体外侵袭和转移能力,可用于模拟体内抗癌药物处理后的癌细胞,并可能为探索化疗后癌症侵袭、转移和复发的机制提供一些新的见解。